GlassScriptPhysician profile
Stephanie Dupre
NPI 1538787247
$4,588.34
in general payments reported to CMS, 2019-2025
43 companies · $484 in 2025
The $484 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,148 · 2022: $1,690 · 2023: $16.56 · 2024: $250 · 2025: $484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $751.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $750.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $549.90 | 2021-2025 | |
| Novo Nordisk INC | $530.87 | 2021-2022 | |
| Glaxosmithkline, LLC. | $353.80 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $272.38 | 2021-2025 | |
| Lilly USA, LLC | $253.43 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $204.12 | 2021-2022 | |
| Astellas Pharma US INC | $193.47 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $178.84 | 2022 | |
| Argenx US, INC. | $125.00 | 2024 | Vyvgart |
| Alexion Pharmaceuticals, INC. | $125.00 | 2024 | Ultomiris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.87 | 2021-2022 | |
| Amarin Pharma, INC. | $113.78 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $111.51 | 2021-2022 | |
| Pfizer INC. | $108.58 | 2021-2022 | |
| Amgen INC. | $108.39 | 2021-2022 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Dupre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.